Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. - GreenMedInfo Summary
Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients.
Eur J Clin Invest. 2020 Jan 21:e13201. Epub 2020 Jan 21. PMID: 31960952
BACKGROUND: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects.
MATERIALS AND METHODS: Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability, and intestinal microbiota were analysed at 0, 30, 45, and 60 days.
RESULTS: Percentage decrease from baseline of abdominal pain (-48.8% vs. -3.5%), bloating (-36.35% vs. +7.35%) and severity of disease (-30.1% vs. -0.4%) was significantly (p<0.0001) greater with LBB than placebo, respectively. In IBS-D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6±0.4 to 4.3±1.1, P<0.00001) than placebo (from 6.2±0.7 to 5.3±1.1, P=0.04). In IBS-C patients, Bristol score tended to improve from baseline after LBB (2.6±1.1 vs. 3.2 ± 0.5, P=0.06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs. 1.1 ± 0.2, p=0.01). During treatment, presumptive lacticacid bacteria and Bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased.
CONCLUSIONS: The novel formulation of B. longum BB536 and L.rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability, and gut microbiota in IBS patients.